<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="129631">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02153476</url>
  </required_header>
  <id_info>
    <org_study_id>VMA-202</org_study_id>
    <nct_id>NCT02153476</nct_id>
  </id_info>
  <brief_title>A Safety And Efficacy Study Of Alg-1001 In Human Subjects With Symptomatic Focal Vitreomacular Adhesion</brief_title>
  <official_title>A Safety And Efficacy Study Of Alg-1001 In Human Subjects With Symptomatic Focal Vitreomacular Adhesion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allegro Ophthalmics, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allegro Ophthalmics, LLC</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the safety and efficacy of ophthalmic intravitreal injection of ALG-1001 in human
      subjects with symptomatic focal vitreomacular adhesion
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2014</start_date>
  <primary_completion_date type="Anticipated">November 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Release of Vitreo Macular Adhesion (VMA)  by Optical Coherence Tomography (OCT)</measure>
    <time_frame>90 Days</time_frame>
    <safety_issue>No</safety_issue>
    <description>The primary endpoint of this study is observation of pharmacologic resolution of VMA, with VMA defined as vitreous adhesion to the macula within a 6mm central retinal field surrounded by elevation of the posterior vitreous cortex as seen on OCT.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>1) Non-surgical closure of full thickness macular holes 2) Best Corrected Visual Acuity (BCVA) 3) Need for pars plana vitrectomy (PPV)</measure>
    <time_frame>90 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The secondary endpoints of this study are the observations of: (a) non-surgical closure of full thickness macular holes; (b) BCVA; and (c) need for pars plana vitrectomy.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Symptomatic Focal Vitreomacular Adhesion</condition>
  <arm_group>
    <arm_group_label>2.0mg of ALG-1001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2.0mg of ALG-1001</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intravitreal injection in 0.05cc balanced salt solution.</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Balanced Salt Solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>2.0mg of ALG-1001</intervention_name>
    <arm_group_label>2.0mg of ALG-1001</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Balanced Salt Solution</intervention_name>
    <arm_group_label>Intravitreal injection in 0.05cc balanced salt solution.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Symptomatic focal vitreomacular adhesion

          2. Vitreomacular traction syndrome

          3. Stage 1 and 2 macular holes, ≤ 350 µm

          4. BCVA of 20/25 Early Treatment Diabetic Retinopathy Study (ETDRS) or     worse in the
             study eye

          5. BCVA of 20/800 ETDRS or better in the fellow eye

          6. Male or female subjects, 18 years of age or older

          7. Signed Informed Consent

        Exclusion Criteria:

          1. High myopes &gt; -8.0 D spherical equivalent

          2. History of prior vitrectomy in the study eye

          3. History of photocoagulation to the retina in the study eye

          4. Macular hole in the study eye &gt; 350 µm

          5. Subjects with epiretinal membranes in the study eye

          6. Subjects with broad VMA, defined as VMA of &gt;1500 µm

          7. Subjects with proliferative Diabetic Retinopathy (DR), neovascular Age-related
             Macular Degeneration (AMD), or retinal vascular occlusion in the study eye

          8. Subjects with aphakia in the study eye

          9. Subjects with uncontrolled glaucoma

         10. Subjects with lenticular or zonular instability

         11. Subjects with prior ocular surgery or intravitreal injection in the study eye within
             90 days of study enrollment

         12. Pregnant or nursing women
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Retina-Vitreous Associates Medical Group</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Boyer, MD</last_name>
      <phone>310-289-2478</phone>
      <phone_ext>1243</phone_ext>
    </contact>
    <investigator>
      <last_name>David Boyer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>California Retina Consultants</name>
      <address>
        <city>Santa Barbara</city>
        <state>California</state>
        <zip>93103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Avery, MD</last_name>
      <phone>805-963-1648</phone>
    </contact>
    <investigator>
      <last_name>Robert Avery, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Center for Retinal and Macular Disease</name>
      <address>
        <city>Winter Haven</city>
        <state>Florida</state>
        <zip>33880</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tolentino, MD</last_name>
      <phone>863-297-5400</phone>
    </contact>
    <investigator>
      <last_name>Mike Tolentino, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Austin Retina Associates</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wong, MD</last_name>
      <phone>512-451-0103</phone>
    </contact>
    <investigator>
      <last_name>Robert Wong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Retina Consultants Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brown, MD</last_name>
      <phone>713-524-3434</phone>
    </contact>
    <investigator>
      <last_name>David Brown, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 30, 2014</lastchanged_date>
  <firstreceived_date>May 27, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tissue Adhesions</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
